# A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

> **NCT03725007** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 124 (estimated)

## Conditions studied

- Juvenile Idiopathic Arthritis (JIA)

## Interventions

- **DRUG:** Upadacitinib

## Key facts

- **NCT ID:** NCT03725007
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-24
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03725007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03725007, "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03725007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*